

CLEO Selects U.S. Clinical Trial Sites

Highlights

- Initial U.S. clinical trial sites contracted following Institutional Review Board (IRB) approval
- 7 sites selected across Texas, Arizona, Florida, Nevada, California, and New York
- First patients being recruited with trials to begin mid-August 2024
- Australian ethics approval also obtained with mirror trial to run at Monash Health.

MELBOURNE, AUSTRALIA, 31 July 2024: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce progress for its U.S. clinical trials in support of its FDA application for its ovarian cancer diagnostic blood test.

U.S. Clinical Trial Sites Selected

CLEO is pursuing regulatory approval in the U.S. as the largest diagnostics market in the world. Prior to submission with the Food and Drug Administration (FDA), the Company will complete a study that will benchmark CLEO's technology through a 500 patient clinical trial. CLEO's U.S.-based clinical trials manager, Lindus Health, has now obtained Institutional Review Board (IRB) approval for, and formally contracted 7 clinical trial sites across the U.S.

This follows CLEO obtaining IRB approval for its clinical trial design last month. A wide geographic range of sites ensures that a diverse representation of the U.S. population is met. Initial sites that have been selected and contracted are located in Texas, Arizona, Florida (x2), Nevada, California, and New York. First patients are being recruited with the trials to begin mid-August 2024.

Commenting on the selection of U.S. trial sites, CLEO Chief Executive, Richard Allman, said:

"This marks the first visible activity by CLEO in the U.S. and effectively a large step in the journey there to bring our ovarian cancer diagnostic blood test to the largest diagnostic market in the world.

We believe that we have a sound strategy and plan that has been supported by the FDA and IRB, and we now move to progress our clinical trials that will ultimately drive our market entry.

I look forward to announcing the start of trial activities in the coming weeks."

Cleo Diagnostics Ltd ASX:COV

Level 2, 480 Collins Street, Melbourne, VIC, 3000
ACN 655 717 169 T +61 3 9614 0600 E office@cleodx.com

Directors

Chair and Non-Executive Director: **Adrien Wing**
Chief Executive Officer and Executive Director: **Dr Richard Allman**
Chief Scientific Officer and Executive Director: **Dr Andrew Stephens**
Non-Executive Director and Lead Medical Advisor: **Professor Tom Jobling**
Non-Executive Director: **Lucinda Nolan**

Australian Clinical Trials

CLEO is also pleased to announce that Human Research Ethics Committee Approval (HREC) has also been obtained for a similar trial design to be conducted in Australia. Whilst the U.S. arm will provide the full complement of samples for CLEO's FDA application, any supplementary samples obtained locally will be used to further refine CLEO's technology and test algorithms prior to commercial launch.

-ENDS-

This ASX announcement was authorised for release on behalf of the CLEO Diagnostics Ltd Board by:
Richard Allman, Chief Executive Officer.

For more information, contact:

Richard Allman
Chief Executive Officer
+613 9614 0600
office@cleodx.com

Elvis Jurcevic
Investor Relations
+614 08 268 271
ej@cleodx.com

Forward Looking Statements: This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Cleo and certain of the plans and objectives of Cleo with respect to these items. These forward-looking statements are not historical facts but rather are based on Cleo's current expectations, estimates and projections about the industry in which Cleo operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Cleo, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Cleo cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Cleo only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Cleo will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

About Cleo Diagnostics Ltd ASX:COV

CLEO aims to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in non-malignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide.

The platform is backed by over 10 years of scientific Research & Development at the Hudson Institute of Medical Research, with two clinical studies conducted with over 500 patients. Pursuant to a licence agreement with the Hudson Institute of Medical Research, CLEO has a worldwide exclusive licence to commercialise the intellectual property which underpins its operations and the ovarian cancer tests.

The clinical unmet worldwide need is urgent. An accurate and early detection blood test could shift survivability for ovarian cancer significantly as seen with other cancers. CLEO is advancing the availability of its simple blood test, under a modular execution strategy which is designed to eventually address all ovarian cancer detection markets with specific tests including surgical triage, recurrence, high risk, and early-stage screening.

